Altasciences Completes Expansion of New State-Of-The-Art Laboratory in Columbia, Missouri
Altasciences is pleased to announce the completion of its laboratory facilities in Columbia, MO.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231031577860/en/
From left to right: Altasciences' Dr. Lynne Le Sauteur, Dr. Susan Ohorodnik, Ian Vanterpool, and Michael Qualls at the bioanalytical laboratory opening in Columbia, Missouri (Photo: Business Wire)
The newly expanded, 8,000-square-foot space, which includes a test material department, features state-of-the-art equipment and forty-eight workbenches, with a vast range of services, including ligand binding assays, flow cytometry, biomarker analysis, and cell culture capabilities.
“This laboratory expansion is a significant step forward in our ability to meet the increasing needs of sponsors. Our focus on growing our bioanalytical capabilities highlights Altasciences' mission to help develop potentially life-saving therapeutics, and get them to market faster,” said Marie-Hélène Raigneau, Co-chief Operating Officer, Altasciences. “Our integrated CRO/CDMO services combine bioanalytical services with preclinical and clinical study solutions, manufacturing services, and all complementary research support services, for maximum efficiency.”
This is Altasciences’ third purpose-built laboratory. Altasciences’ laboratory sciences has the scientific, regulatory, and operational expertise for quantitation of drugs and biomarkers from discovery to preclinical to Phase IV, using bioanalysis platforms including mass spectrometry, ligand binding assay, PCR, flow cytometry, ELISpot, and cell based assays in routine and specialized areas such as immunomodulation and cell and gene therapy. All three laboratories across North America are uniformly designed and managed.
Whether as a standalone bioanalytical service or as part of an integrated program, Altasciences provides top-quality data for TK, PK, and PD determinations to support preclinical and clinical studies.
Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster. To learn more about Altasciences, visit altasciences.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
+1 514 601-9763
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VIOOH Shares Industry-first Carbon Emissions Measurement Hitting 18% Below Benchmark11.12.2023 09:00:00 CET | Press release
Today, VIOOH, the leading premium global digital out of (DOOH) home supply-side platform, announced a partnership with the Carbon Intelligence Platform, Cedara, a supporter of Ad Net Zero. In an industry first for a programmatic DOOH (prDOOH) player, VIOOH has shared publicly its impression intensity carbon emissions (grams CO2e) per ad impression for 2022, which is 18% below the programmatic open web benchmark. Based on Cedara’s measurement, VIOOH generated 0.28 grams CO2e per ad impression in 2022, well below the Cedara ad platform benchmark of 0.34, which is based on programmatic open web vendor data. VIOOH worked closely with Cedara on a comprehensive greenhouse gas (GHG) inventory assessment across its operations, including programmatic media activity, which contributes the majority of Scope 3 emissions. As part of its measurement process, Cedara not only analysed data sets from business operations, but also activity data from media delivery, data centres, and media owners, amongs
Hexadrone Starts C5 and C6 Drone Type Examination After Successful GAP Analysis of The TUNDRA 2’ Specification by Notified Body11.12.2023 08:30:00 CET | Press release
Hexadrone SAS, A French Modular UAV’s Manufacturer Created in 2014 has successfully completed GAP Analysis for The Tundra 2 in its Urban and Endurance versions versus DR EU 2019/945 with intension for Class Identification Label C5 and C6. With the achievement of this milestone, the certification process for both Urban and Endurance Version have been now formally triggered by Hexadrone to be performed by the notified body NavCert GmbH. The Tundra 2 is bringing on the market a key differentiator by providing extreme modularity on UAVs, integrating unlimited type of payloads used in various sectors like, Surveillance, Geospatial, Agriculture, Oil and gas, Military, Homeland security, Rescue and much more. “Through an in-depth analysis based on European Union (EU) Regulation 2019/945, we have ensured that the specifications of the Tundra 2 as well as our user manuals fully meet the current requirements. This compliance will ensure that the TUNDRA 2 users will be able to fly in European air
VINSSEN Co., Ltd. Successfully Supplies Hydrogen Fuel Cell for Industry Project in Singapore11.12.2023 08:00:00 CET | Press release
VINSSEN Co., Ltd. (CEO Chil-Han Lee), a company specializing in the production of electric and hydrogen hybrid propulsion systems, has successfully tested and delivered a hydrogen fuel cell system for a trial project involving several key industry partners. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231210481971/en/ Hydrogen fuel cell power generation equipment is undergoing inspection before delivery (Photo: VINSSEN Co., Ltd.) VINSSEN is collaborating with Shell Singapore Pte. Ltd. (Shell) as the project sponsor, Seatrium Limited as the project developer, Penguin International Limited as the owner and operator of the vessel, and Air Liquide Singapore Private Limited as the hydrogen supplier. This project is a pilot to test the use of hydrogen fuel cells in maritime applications, marking the first step in confirming feasibility of hydrogen as a marine fuel. The hydrogen fuel cell system has been delivered from Korea and
New Study Finds Significant Correlation Between Masimo ORi™ and Arterial Partial Pressure of Oxygen During One-Lung Ventilation11.12.2023 08:00:00 CET | Press release
Masimo (NASDAQ: MASI) today announced the findings of a retrospective study published in the Journal of Anesthesia in which Dr. Yu Jeong Bang and colleagues at the Samsung Medical Center, Sungkyunkwan University School of Medicine, in Seoul, South Korea, investigated the association of Masimo ORi™ and the arterial partial pressure of oxygen (PaO2) in 554 patients who underwent non-cardiac thoracic surgery during one-lung ventilation (OLV), making this study the largest to date on ORi. The researchers found that ORi values “were significantly correlated with PaO2 measured simultaneously” and that ORi “could provide useful information on arterial oxygenation even during one-lung ventilation.”1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231210873994/en/ Masimo Root® with ORi™ (Photo: Business Wire) Noninvasive, continuous Masimo ORi provides continuous, real-time insight into the oxygenation of hemoglobin in the moderate hy
Ferring and PharmaBiome Enter Into a New Microbiome R&D Collaboration and Exclusive Licensing Agreement11.12.2023 07:00:00 CET | Press release
Ferring Pharmaceuticals and Zürich-based microbiome translation company PharmaBiome are today announcing a research and development collaboration to drive forward new microbiome-based biotherapeutics in the field of gastroenterology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231210383233/en/ The deal provides Ferring with exclusive rights to develop, manufacture and commercialise next generation microbiome-based therapeutics within the field of gastroenterology arising out of the collaboration. The financial details of this deal are undisclosed. “This agreement is the latest in Ferring’s long term mission to maximise the therapeutic potential of the gut microbiome for the benefit of patients. PharmaBiome’s unique technology enables identification and manufacturing of defined consortium live microbiome biotherapeutics that could reverse microbiome dysbiosis linked to disease,” said Carl Bilbo, Senior Vice President, Micr